![Elisa Agostinetto: CDH1 truncating mutations were associated with poor prognosis](https://oncodaily.com/pub/uploads/2024/08/52509b969df2e6f6b3613602363e2466-1473x750.png-1280x652.webp)
Elisa Agostinetto: CDH1 truncating mutations were associated with poor prognosis
Elisa Agostinetto shared a paper by Lounes Djerroudi et al. on X:
“CDH1 alterations are common in lobular BC, but the precise mutational status of CDH1 can tell us more. In this work by Curie Institute, CDH1 truncating mutations were associated with radiohistologic size discordance and poor prognosis.”
Source: Elisa Agostinetto/X
Authors: Lounes Djerroudi, Amel Bendali, Laetitia Fuhrmann, Camille Benoist, Gaelle Pierron, Julien Masliah-Planchon, Yann Kieffer, Matthieu Carton, Jean-Christophe Tille, Joanna Cyrta, Toulsie Ramtohul, Claire Bonneau, Martial Caly, Victor Renault, François-Clément Bidard, Fatima Mechta-Grigoriou, Anne Vincent-Salomon
E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma
Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care.
Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.